Hoffmann-La Roche
Prof.dr. V.C.G. Tjan-Heijnen (NL)
J. Neuteboom (Roche Nederland B.V.) A.E. van Leeuwen-Stok (BOOG Study Center)
BREAST
Roche Nederland B.V.
A prospective, two-arm, randomized, multicenter, multinational, double-blind, placebo-controlled study in patients with HER2-positive primary breast cancer who have had excision of their tumor. Arms Experimental: 1 Drug: pertuzumab 840 mg iv loading dose in Cycle 1, followed by 420 mg iv every 3 weeks, 52 weeks Drug: trastuzumab [Herceptin] 8 mg/kg iv loading dose in Cycle 1, followed by 6 mg/kg iv every 3 weeks, 52 weeks Drug: Chemotherapy 6-8 cycles of standard chemotherapy (non-anthracycline based or anthracycline-based) Placebo Comparator: 2 Drug: placebo iv every 3 weeks, 52 weeks Drug: trastuzumab [Herceptin] 8 mg/kg iv loading dose in Cycle 1, followed by 6 mg/kg iv every 3 weeks, 52 weeks Drug: Chemotherapy 6-8 cycles of standard chemotherapy (non-anthracycline based or anthracycline-based)
PRIMARY OBJECTIVES To compare invasive disease-free survival (IDFS) in patients with HER2-positive breast cancer randomized to chemotherapy plus one year of trastuzumab plus placebo or chemotherapy plus one year of trastuzumab plus pertuzumab. SECONDARY OBJECTIVES To compare invasive disease-free survival including second non-breast cancers, disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI), cardiac safety, overall safety and health-related quality of life (HRQL) in the two treatment arms.
Primary Endpoint
InvasiveDisease-free Survival(IDFS)
Secundary Endpoints
Main inclusion criteria: Adult patients. >/= 18 years of age Non-metastatic primary invasive HER2-positive carcinoma of the breast that is adequately excised, and that is either node-positive (except T0) or node-negative but with presence of at least one risk factor as defined by the protocol Eastern Cooperative Oncology Group (ECOG) performance status </=1 The interval between definitive surgery for breast cancer and randomization must be at least 3 weeks but no more than 7 weeks and the patient must be willing and able to start treatment within 1 week of randomization Known hormone receptor status (estrogen receptor and progesterone receptor) Baseline LVEF >/= 55% Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the patient and/or partner for the duration of the study treatment and for at least 6 months after the last dose of study drug Main exclusion criteria: History of any prior (ipsi- and/or contralateral) invasive breast cancer History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin Any “clinical” T4 tumor as defined by TNM, including inflammatory breast cancer Any previous systemic chemotherapy for cancer or radiotherapy for cancer Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer Concurrent anti-cancer treatment in another investigational trial Serious cardiac or cardiovascular disease or condition Pregnant or lactating women
